Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 72.4% in May

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totaling 19,453 shares, a drop of 72.4% from the April 30th total of 70,535 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 159,209 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

A number of equities analysts have commented on XTNT shares. BTIG Research reissued a “buy” rating and issued a $1.00 price objective on shares of Xtant Medical in a research note on Wednesday, May 13th. Craig Hallum reissued a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $1.00.

Institutional Investors Weigh In On Xtant Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XTNT. Jane Street Group LLC bought a new stake in Xtant Medical during the 2nd quarter valued at about $26,000. Nantahala Capital Management LLC lifted its holdings in Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after buying an additional 57,000,000 shares in the last quarter. Mink Brook Asset Management LLC lifted its holdings in Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after buying an additional 104,159 shares in the last quarter. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in Xtant Medical during the 4th quarter valued at about $220,000. Institutional investors own 69.33% of the company’s stock.

Xtant Medical Stock Performance

Shares of NYSEAMERICAN:XTNT opened at $0.47 on Friday. Xtant Medical has a 52 week low of $0.44 and a 52 week high of $0.95. The stock has a market capitalization of $65.92 million, a P/E ratio of 47.05 and a beta of -0.11. The firm has a fifty day simple moving average of $0.51 and a two-hundred day simple moving average of $0.61. The company has a quick ratio of 1.64, a current ratio of 3.34 and a debt-to-equity ratio of 0.17.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings results on Wednesday, May 13th. The medical device company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02). Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%. The firm had revenue of $20.88 million during the quarter, compared to analysts’ expectations of $20.16 million.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.